Fibroblast growth factor-2 and cardioprotection

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Molecular Cardiology

Background:

• Myocardial resistance to ischemic damage is crucial for preventing heart failure.
• Ischemic and pharmacological conditioning are established acute cardioprotective strategies.
• Regenerative and angiogenic responses offer sustained benefits for damaged hearts.

Purpose of the Study:

• To review the therapeutic potential of low molecular weight fibroblast growth factor-2 (lo-FGF-2) for cardiac protection.
• To highlight lo-FGF-2's cytoprotective and regenerative properties.
• To present lo-FGF-2 as a promising agent for acute and sustained cardiac benefits.

Main Methods:

• Review of experimental cardiology findings on cardioprotective agents.
• Analysis of fibroblast growth factor-2 (FGF-2) functions, including its isoforms.
• Examination of clinical trial data regarding FGF-2 safety and efficacy.

Main Results:

• Fibroblast growth factor-2 (FGF-2) demonstrates direct pro-survival effects during ischemic events.
• FGF-2 is a potent angiogenic factor, crucial for cell proliferation and survival.
• Human clinical trials indicate a favorable safety profile for FGF-2.

Conclusions:

• Low molecular weight fibroblast growth factor-2 (lo-FGF-2) exhibits significant cytoprotective and regenerative capabilities.
• lo-FGF-2 holds promise as a therapeutic agent for acute and chronic cardiac protection.
• This isoform represents a novel strategy to ameliorate cardiac pathologies and prevent heart failure progression.